Key result
Aspirin resistance lacks standardized diagnostic testing and tailored management due to conflicting clinical evidence.
Why the study?
Aspirin resistance in patients with coronary artery disease shows variable platelet response and unclear clinical impact, with no accepted evaluation method or treatment guidelines.
This review highlights the lack of standardized diagnostic methods and conflicting clinical data regarding aspirin resistance, which currently precludes the formulation of specific treatment guidelines for affected patients.
Answers are grounded in this paper and cite their sources.
Absence of standardized diagnostics precludes routine testing or management changes; leaves open the clinical impact of aspirin resistance in CVD.
Aspirin is the cornerstone of treatment in patients with coronary artery disease. However, several studies investigating the in vitro response of platelets to the administration of aspirin showed this response to be variable, with some patients exhibiting non-responsiveness or resistance. Aspirin resistance may be categorised as either 'laboratory' or 'clinical'. Laboratory aspirin resistance is defined as the failure of aspirin to inhibit the production of thromboxane A(2) (TxA(2)) by platelets or to inhibit platelet activation that depends on TxA(2) production. Clinical aspirin resistance is defined as the failure to prevent the occurrence of atherothrombotic ischaemic episodes in patients to whom it is administered. So far, there is no generally accepted method for the ex vivo evaluation of platelet activation or for assessing the degree of platelet activation following aspirin administration and data concerning the clinical impact of aspirin resistance are conflicting. For these reasons it is not possible to suggest specific guidelines for the treatment of patients who show high levels of platelet activation or a low level of platelet inhibition after treatment with aspirin. The aim of this review is to present data from laboratory and clinical studies that are related to resistance to aspirin, and to discuss the possible causes, the clinical significance, and the ways of managing such resistance at a clinical level.
No takes yet. Share an insight, caveat, or question.
Papathanasiou et al. (2009) conducted a review in Coronary artery disease. Aspirin was evaluated. Aspirin resistance lacks a standardized diagnostic method and specific management guidelines due to conflicting data on its clinical impact in patients with cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: